U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07781345) titled 'A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)' on July 31.
Brief Summary: The primary purpose of the study is to describe the incidence and severity of known adverse events (AEs), including Amyloid-Related Imaging Abnormalities Oedema/Effusion (ARIA-E), Amyloid-Related Imaging Abnormalities-Microhemorrhage and Haemosiderin Deposit (ARIA-H), intracerebral hemorrhage greater than (>) 1 centimeter (cm) in diameter, and anaphylaxis (stratified by apolipoprotein E4 variant [APOE4] genotype, concomitant antithrombotic therapy, and comorbid Cerebral Amyloid Angiopathy [CAA]), of LEQEMBI ...